Following the cloning of the human EPO gene (Lin et al., 1985; Jacobs et al., 1985), recombinant human EPO was approved for clinical use by the United States Food and Drug Administration in 1989 primarily for treatment of anemia associated with chronic renal disease. Here, EPO is linked to anemia.